Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9664.124 | 1.0394 | 1.0938 | 0.8433 | |
| MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9664.124 | 0.9955 | 0.9894 | 0.8433 | |
| MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9664.124 | 1.0191 | 1.0453 | 0.8433 | |
| MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9664.124 | 0.9810 | 0.9551 | 0.8433 | |
| MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9664.124 | 1.0381 | 1.0907 | 0.8433 | |
| MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9664.124 | 1.0216 | 1.0512 | 0.8433 | |
| MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9664.124 | 1.0052 | 1.0123 | 0.8433 | |
| MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 9664.124 | 1.0560 | 1.1334 | 0.8433 | |
| MDA-MB-415 | HR+ | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 9664.124 | 0.9750 | 0.9407 | 0.8433 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7898.018 | 0.9680 | 0.9432 | 1.1279 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7898.018 | 1.0605 | 1.1069 | 1.1279 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7898.018 | 1.0113 | 1.0201 | 1.1279 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7898.018 | 1.0245 | 1.0434 | 1.1279 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7898.018 | 1.0709 | 1.1253 | 1.1279 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7898.018 | 1.0208 | 1.0369 | 1.1279 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7898.018 | 0.9960 | 0.9929 | 1.1279 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 7898.018 | 1.0649 | 1.1147 | 1.1279 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 7898.018 | 0.9765 | 0.9583 | 1.1279 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7899.018 | 0.9447 | 0.9451 | 2.0432 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7899.018 | 1.0968 | 1.0925 | 2.0432 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7899.018 | 0.8817 | 0.8805 | 2.0432 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7899.018 | 1.0646 | 1.0622 | 2.0432 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7899.018 | 1.0292 | 1.0283 | 2.0432 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7899.018 | 1.0542 | 1.0523 | 2.0432 | |
| MDA-MB-436 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7899.018 | 0.9506 | 0.9510 | 2.0432 |